GLPwatch

Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.

Neuroscience · 2025

Last updated 2026-05-28

Semaglutide is a GLP-1 drug approved to help manage blood sugar in people with diabetes. Research suggests it may also protect the brain and improve thinking by affecting certain harmful processes linked to diabetes-related nerve damage, though the exact ways it works are not fully understood.

AI summary of the abstract below.

JournalNeuroscience, 2025
Citations2
Molecules semaglutide
Conditions studied Alzheimers, Parkinsons

Abstract

Neuronal injury is a common complication in patients with diabetes. These injuries include a wide range of neurobehavioral complications that significantly reduce the neuronal network efficiency and quality of life in affected individuals. Currently, diabetes-induced neuronal complications are a major global health challenge, and many studies have been performed to prevent or slow their progression. Semaglutide is a novel form of glucagon-like peptide-1 (GLP-1) agonist agents that has recently been approved for diabetic patients to normalize glucose metabolism. However, some evidence indicates that it has extra-glycemic effects in some tissues as well as in the central nervous system. This evidence suggests that semaglutide can suppress some pathophysiological pathways involved in diabetes-induced neuronal complications and thus improve neuronal network efficiency. However, there is limited evidence to support all the pathways involved in mediating these benefits. In the current review, we aim to present the latest clinical and experimental findings on the possible benefits of semaglutide on major neuronal complications and to determine the possible molecular mechanisms involved.

Verbatim abstract via PubMed 40494410 ↗

Related research